Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Special Lecture

Rhizoxin, a Macrocyclic Lactone Antibiotic, as a New Antitumor Agent against Human and Murine Tumor Cells and Their Vincristine-resistant Sublines

Takashi Tsuruo, Tomoko Oh-hara, Harumi Iida, Shigeru Tsukagoshi, Zenji Sato, Izumi Matsuda, Shigeo Iwasaki, Shigenobu Okuda, Fusaaki Shimizu, Kazuhiko Sasagawa, Masaharu Fukami, Kuniaki Fukuda and Masao Arakawa
Takashi Tsuruo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tomoko Oh-hara
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Harumi Iida
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shigeru Tsukagoshi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zenji Sato
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Izumi Matsuda
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shigeo Iwasaki
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shigenobu Okuda
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fusaaki Shimizu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kazuhiko Sasagawa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masaharu Fukami
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kuniaki Fukuda
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masao Arakawa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published January 1986
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Rhizoxin, isolated from a plant pathogenic fungus which causes rice seedling blight, inhibits the mitosis of the tumor cells in a manner similar to that of Vinca alkaloids as revealed by morphological study and flow cytometry analysis. This new 16-membered macrocyclic lactone showed similar chemotherapeutic effects to those of vincristine against L1210 and P388 leukemia-bearing mice. The drug is also effective against B16 melanoma inoculated i.p. or s.c. Rhizoxin, in contrast to the ansamacrolide, maytansine, was effective against human and murine tumor cells resistant to vincristine and Adriamycin in vitro and in vivo. A maximum 60% increase in life span was obtained in mice inoculated with P388 leukemia resistant to vincristine. Rhizoxin showed greater cytotoxicity in cultured tumor cells than did vincristine. Rhizoxin seems to bear consideration for further development as a new chemotherapeutic agent.

Footnotes

  • ↵1 To whom requests for reprints should be addressed.

  • Received March 29, 1985.
  • Revision received September 10, 1985.
  • Accepted September 13, 1985.
  • ©1986 American Association for Cancer Research.
PreviousNext
Back to top
January 1986
Volume 46, Issue 1
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)

Sign up for alerts

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Rhizoxin, a Macrocyclic Lactone Antibiotic, as a New Antitumor Agent against Human and Murine Tumor Cells and Their Vincristine-resistant Sublines
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Rhizoxin, a Macrocyclic Lactone Antibiotic, as a New Antitumor Agent against Human and Murine Tumor Cells and Their Vincristine-resistant Sublines
Takashi Tsuruo, Tomoko Oh-hara, Harumi Iida, Shigeru Tsukagoshi, Zenji Sato, Izumi Matsuda, Shigeo Iwasaki, Shigenobu Okuda, Fusaaki Shimizu, Kazuhiko Sasagawa, Masaharu Fukami, Kuniaki Fukuda and Masao Arakawa
Cancer Res January 1 1986 (46) (1) 381-385;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Rhizoxin, a Macrocyclic Lactone Antibiotic, as a New Antitumor Agent against Human and Murine Tumor Cells and Their Vincristine-resistant Sublines
Takashi Tsuruo, Tomoko Oh-hara, Harumi Iida, Shigeru Tsukagoshi, Zenji Sato, Izumi Matsuda, Shigeo Iwasaki, Shigenobu Okuda, Fusaaki Shimizu, Kazuhiko Sasagawa, Masaharu Fukami, Kuniaki Fukuda and Masao Arakawa
Cancer Res January 1 1986 (46) (1) 381-385;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Special Lecture

  • Reducing the “Risk” of Chemoprevention: Defining and Targeting High Risk—2005 AACR Cancer Research and Prevention Foundation Award Lecture
  • Enzyme Induction and Dietary Chemicals as Approaches to Cancer Chemoprevention: The Seventh DeWitt S. Goodman Lecture
  • The Pezcoller Lecture: Cancer Cell Cycles Revisited
Show more 3

Articles

  • Reducing the “Risk” of Chemoprevention: Defining and Targeting High Risk—2005 AACR Cancer Research and Prevention Foundation Award Lecture
  • Enzyme Induction and Dietary Chemicals as Approaches to Cancer Chemoprevention: The Seventh DeWitt S. Goodman Lecture
  • The Pezcoller Lecture: Cancer Cell Cycles Revisited
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement